Randomized Anastrozole Exercise Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, phase III trial of a 12 week exercise program, followed by a 36 week voluntary, self-directed exercise program (total 48 weeks) compared to standard supportive care. The purpose of the trial is to determine whether the exercise program is better than standard supportive care to decrease the muscle and joint aches (musculoskeletal symptoms) that result from aromatase inhibitors.

Hypothesis An exercise program that includes stretching, strengthening and aerobic components may improve physical quality of life among women with musculoskeletal symptoms who are taking aromatase inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Activity Program During Aromatase Inhibitor Therapy

NCT03786198

Early Breast Cancer

COMPLETED NA

The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.

NCT02057536

Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness

COMPLETED NA

Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors

NCT00738998

Breast Cancer

TERMINATED NA

Exercise Training in Postmenopausal Patients With Breast Cancer

NCT01384838

Physical Activity

COMPLETED NA

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

NCT00031811

Breast Cancer Menopausal Symptoms Osteoporosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Musculoskeletal Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Arm A: Standard Supportive Care (no supervised exercise)

Group Type ACTIVE_COMPARATOR

Supportive Care

Intervention Type OTHER

B

Arm B: Exercise Intervention

Group Type EXPERIMENTAL

Exercise

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise

Intervention Type OTHER

Supportive Care

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who have been on an adjuvant AI for at least 6 weeks.
* The presence of some musculoskeletal symptoms.
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1
* ER and or PgR positive early breast cancer, stages I, II or III
* Completion of any adjuvant chemotherapy (if given) and primary breast cancer surgery.
* Be willing to switch to Anastrozole if on another AI
* Signed written informed consent

Exclusion Criteria

* Metastatic disease (no imaging or labs required in absence of clinical suspicion of metastases)
* Evidence or history of inflammatory arthropathy (for example, rheumatoid arthritis)
* Any medical condition (for example, significant heart disease) that would prevent a subject from completing an exercise program.
* Unable to take Aromatase Inhibitor (AI)
* Planned secondary reconstruction procedures during the 48 week study period
* Any medical, physical, geographic, emotional, or economic condition that in the judgement of the clinician/study doctor, would make an individual unable or unlikely to be able to exercise three times a week for 12 weeks.
* Unable to complete a study log book and questionnaires (unable to read and write English and no one at home who can adequately do so).
* The use of any exogeneous estrogen and/or progesterone except Estring and natural plant estrogens

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No